Hosted on MSN2h
Celltrion envisions 13 new drugs; Samsung Bio unveils 6th plant plan
Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...
At 7, I Had 6 Months to Live. One Call Changed Everything
Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New ...
Targeted Oncology6d
FDA Clears Investigational New Drug Application for REC-4539 in SCLC
The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...
Targeted Oncology1d
FDA Grants Clearance for Phase 1b/2 Trial of SNB-101 in SCLC
The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...
Business Wire23d
Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as ...
The U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin ...
Solid Biosciences Gains FDA Clearance for New Drug Application
Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.
manilatimes1d
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...
Crain's Chicago Business1d
AbbVie keeps adding cancer treatments with $1B licensing deal for new drug
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...
Solid Biosciences: Promising Advancements in Gene Therapy and Strategic Positioning Justify Buy Rating
Joon Lee, an analyst from Truist Financial, has initiated a new Buy rating on Solid Biosciences (SLDB).Stay Ahead of the Market:Discover ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...